PHIBRO ANIMAL HEALTH CORP-APAHC
ASignal's systematic analysis rates PAHC as Neutral.
Reflects the latest available analysis · analyzed Sep 16, 2026
The case on PAHC
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong return on equity (29.72%) indicating efficient capital use
- Low forward P/E of 9.10x suggesting undervaluation relative to earnings
- High financial health score (0.55) and solid current ratio (2.96x)
- Earnings growth of 24.6% year-over-year outpacing revenue growth
- Negative free cash flow (-$19.30M) raising sustainability concerns
- High debt-to-equity ratio (2.06x) indicating elevated leverage
- Price below 20-day SMA and EMA, signaling near-term downtrend
- MACD below signal line with negative histogram, indicating weakening momentum
- Zero Reddit mentions suggesting lack of retail investor interest
See the full verdict on PAHC
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes PAHC
Most investors never get a second opinion, let alone several. ASignal runs PAHC past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.